John L. Johnson
University of Pennsylvania
27 Papers
5 Citations
John L. Johnson is an academic researcher from University of Pennsylvania. The author has contributed to research in topics: Immune system & Medicine. The author has an hindex of 11, co-authored 22 publications. Previous affiliations of John L. Johnson include Arizona State University & Boston Children's Hospital.
Chat about Author
Papers
TCF-1-Centered Transcriptional Network Drives an Effector Versus Exhausted CD8 T Cell-Fate Decision
Zeyu Chen,Zhicheng Ji,Shin Foong Ngiow,Sasikanth Manne,Zhangying Cai,Alexander C. Huang,John L. Johnson,Ryan P. Staupe,Bertram Bengsch,Caiyue Xu,Sixiang Yu,Makoto Kurachi,Ramin S. Herati,Laura A. Vella,Laura A. Vella,Amy E. Baxter,Jennifer E. Wu,Omar Khan,Jean Christophe Beltra,Josephine R. Giles,Erietta Stelekati,Laura M. McLane,Chi Wai Lau,Xiaolu Yang,Shelley L. Berger,Golnaz Vahedi,Hongkai Ji,E. John Wherry +27 more
TL;DR: A role for TCF-1 in early-fate-bifurcation-driving Tex precursor cells is defined and PD-1 is identified as a protector of this early TCf-1 subset.
531
Lipid nanoparticles enhance the efficacy of mRNA and protein subunit vaccines by inducing robust T follicular helper cell and humoral responses
Mohamad-Gabriel Alameh,István Tombácz,Emily Bettini,Katlyn Lederer,Chutamath Sittplangkoon,Joel R. Wilmore,Brian T. Gaudette,Ousamah Younoss Soliman,Matthew Pine,Philip Hicks,Tomaz B. Manzoni,James J. Knox,John L. Johnson,Dorottya Laczkó,Hiromi Muramatsu,Benjamin Davis,Wenzhao Meng,Aaron M. Rosenfeld,Shirin Strohmeier,Paulo J.C. Lin,Barbara L. Mui,Ying K. Tam,Katalin Karikó,Alain Jacquet,Florian Krammer,Paul Bates,Michael P. Cancro,Drew Weissman,Eline T. Luning Prak,David Allman,Michela Locci,Norbert Pardi +31 more
TL;DR: In this article, a lipid nanoparticle (LNP)-encapsulated nucleoside-modified mRNA vaccines have shown great efficacy against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), but the mechanism of action of this vaccine platform is not well-characterized.
396
Lineage-Determining Transcription Factor TCF-1 Initiates the Epigenetic Identity of T Cells
John L. Johnson,Georgios Georgakilas,Jelena Petrovic,Makoto Kurachi,Stanley Cai,Christelle Harly,Warren S. Pear,Avinash Bhandoola,E. John Wherry,Golnaz Vahedi +9 more
TL;DR: The results indicate that a mechanism by which TCF‐1 controls T cell fate is through its widespread ability to target silent chromatin and establish the epigenetic identity of T cells.
198
Combination immunotherapy with α-CTLA-4 and α-PD-L1 antibody blockade prevents immune escape and leads to complete control of metastatic osteosarcoma.
TL;DR: Combinational immunotherapy approaches to block additional inhibitory pathways in patients with metastatic osteosarcoma may provide new strategies to enhance tumor clearance and resistance to disease.
The Transcription Factor T-bet Resolves Memory B Cell Subsets with Distinct Tissue Distributions and Antibody Specificities in Mice and Humans.
John L. Johnson,Rebecca L. Rosenthal,James J. Knox,Arpita Myles,Martin S. Naradikian,Joanna Madej,Mariya Kostiv,Aaron M. Rosenfeld,Wenzhao Meng,Shannon R. Christensen,Scott E. Hensley,Jonathan W. Yewdell,David H. Canaday,Jinfang Zhu,Adrian B. McDermott,Yoav Dori,Max Itkin,E. John Wherry,Norbert Pardi,Drew Weissman,Ali Naji,Eline T. Luning Prak,Michael R. Betts,Michael P. Cancro +23 more
TL;DR: T-bet expression distinguishes MBC subsets that have profoundly different homing, residency, and functional properties, and mediate distinct aspects of humoral immune memory.
176